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Abstract Due to lack of evidence from prospective clini-
cal trials, the diagnostic procedures, their frequency, as 
well as the length of the follow-up period in cutaneous 
melanoma patients should be based on the individual 
risk of disease recurrence, which is strongly dependent 
on the stage of disease at the time of diagnosis. In the 
paper we propose the current recommendations for 
follow-up strategy. Nowadays, new effective treatment 
options with biological agents justify the closer monitor-
ing of high risk melanoma patients.
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Due to the absence of clear evidence from prospective 
clinical trials, the recommendations for melanoma fol-
low-up are mainly based on the retrospective analyses 
of prognostic factors (e.g., stage of melanoma) and the 
onset of disease recurrence [1–5]. Other factors, such 
as the presence of dysplastic nevi, family history, and 
patient or physician concerns will impact follow-up 
schedule as well.
The types of diagnostic procedures, their frequency, as 
well as the length of follow-up period should be based 
on the individual risk of disease recurrence [5–10]. The 
risk of recurrence and survival is strongly dependent on 
the stage of disease at the time of diagnosis and is sig-
nificantly higher after surgical resection of metastases to 
regional lymph node than in T1–T2 patients with negative 
sentinel lymph node [11–15]. Of note, the 5-year recur-
rence free survival in IIIA, IIIB, IIIC stages (according to 
American Joint Committee on Cancer—AJCC) is equal to 
50–63 %, 26–32 % and 11–12 % as compared with 5-year 
recurrence free survival in stages IA, IB, and IIA equal to 
95 %, 82 %, 72 %, respectively [2, 6, 13, 15, 16]. Because the 
recurrence rate is the highest in the first 2–3 years after 
treatment, follow-up visits must be intensified in this 
period [17, 18].
The main goal of the follow-up is to detect a locore-
gional relapse possible to be treated surgically [1, 9, 12, 
13, 16, 17, 19, 20]. The most common site of the first 
relapse is local relapse or in-transit metastases (20–28 % 
of patients), more than 25 % of patients have regional 
lymph node involvement and 15–50 % of cases present 
distant metastases. The percentage of relapse to regional 
lymph node has been reduced after the introduction of 
sentinel node biopsy as a standard of care. What is impor-
tant, a large portion of local and locoregional recurrence 
can be detected by the patient alone (more than 60 % of 
cases). Therefore, the patients’ education in self-control 
is obligatory, especially the careful assessment of the 
regional lymph basin and the scar after primary site exci-
sion must be performed every 3–6 months. After 5 years 
of observation, in patients with successfully treated stage 
I–III melanoma, the probability of recurrence is less than 
5 % [9, 20]. However, it may occur even many years after 
the diagnosis with equal distribution between locore-
gional recurrence and disease dissemination.
In oncological centers, the control visits for asymp-
tomatic patients are routinely performed every 3 months 
during the first 2 years of follow-up, then every 6 months 
for the next 3 years and once a year—after 5 years of 
observation. Patients with melanoma in-situ do not 
require so long-term observations, except for patients 
with the presence of multiple atypical skin nevi or other 
risk factors. Due to low risk of recurrence, the frequency 
of control visits also should be limited to 1–2 visits per 
year (every 6–12 months) in melanoma stage IA [2, 6, 21]. 
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In this group of patients, there is no indication to perform 
any additional tests except history and physical examina-
tion (H&P) and self-examination and the less intensive 
control schemes have no negative impact on survival [6, 
21–23].
During the follow-up visit, it is obligatory to exclude 
the locoregional recurrence and disease dissemina-
tion. The careful assessment of the scar and the regional 
lymph nodes/lymphatic inflow (spread in-transit) must 
be performed; ultrasound examination can be utilized. 
Ultrasound assessment of lymphatic basin has high 
sensitivity and specificity [24–26]. It is especially useful 
in cases not undergoing sentinel node biopsy, because 
the nodal recurrences in the lymphatic basin after nega-
tive sentinel node biopsy usually do not exceed 5 % [27]. 
Moreover, it has been shown that sentinel lymph node 
dissection reduces subsequent regional lymph node 
metastases [28, 29].
For the detection of lung metastasis the specificity 
of chest X-ray is only about 50 %, therefore, this exami-
nation is of little value in asymptomatic patients with 
skin melanoma in stage I–II. It has been suggested, that 
approximately 68 % of recurrences are detected on the 
basis of clinical symptoms, 26 % due to physical examina-
tion (often by the patients who found the subcutaneous 
tumor), and only 6 % due to chest X-ray. Moreover, data 
show that there are no positron emission tomography 
(PET) tests in order to control patients’ disease recur-
rence after treatment of primary cutaneous melanoma.
In patients with detected locoregional recurrence—
stage III (without any other findings in H&P, lactated 
dehydrogenase serum tests, or chest X-ray), the com-
puted tomography (CT) of chest, abdomen, and pelvis 
may initially detect distant disease dissemination in 
only 7 % of patients [30, 31]. However, during follow-up 
in stage III patients the asymptomatic relapse can be 
revealed with CT scans in 72 % [16], which justifies the 
recommendation of using chest and abdomen CT imag-
ing for early detection of disease recurrence in this group 
of patients [17]. In this group of patients (with exception 
of IIIC stage), the role of the brain CT or magnetic reso-
nance imaging (MRI) is not clear, especially taking into 
account the cost-effectiveness ratio. In stage IIIC mela-
noma patients Romano et al. found the risk of recur-
rence in the form of brain metastases in more than 5 % 
during the first 13 months after locoregional therapy; 
Table 1 Follow-up recommendation in melanoma patients according to American Joint Committee on Cancer (AJCC) staging 
group
Recommendation Time-line
Early stage melanoma (stage IA(–IB) according 
to AJCC)—after primary site resection.
In resected low-risk melanomas (pT1A-B), there is no indication to perform any ad-
ditional tests except history and physical examination (H&P).
H&P with attention to complete skin exam, as well as draining lymph nodes, locore-
gional area, and scar after primary site resection.
Routine imaging/lab tests not recommended.
Ultrasound of regional lymph nodes only in case of pT1b melanoma without sentinel 
lymph node procedure.
Specific signs or symptoms are indications for additional radiologic imaging.
Chest X-ray—optional.
Patients education towards skin self-examination mandatory.
Stage IB may be grouped with stage II patients due to higher risk of recurrence.
Every 6–12 months 
for 5 years; and an-
nually thereafter, as 
clinically indicated.
Locally advanced melanoma no regional 
metastases detected [stage (IB) IIA–IIC]—after 
primary site resection and SNB.
H&P with attention to complete skin exam, as well as draining lymph nodes, locore-
gional area, and scar after primary site resection.
During the first three years, in IIB-IIC melanoma, CT and/or ultrasound every 6–12 
months and annual brain MRI can be considered to screen for recurrent or metastatic 
disease at the discretion of the physician.
Chest X-ray—optional.
CBC (Complete Blood Count), Liver Function Tests (LFT) and LDH level—optional.
Patients education towards skin self-examination mandatory.
Stage IIC may follow stage III recommendations due to higher risk of recurrence than 
stage IIIA.
Every 3–6 months 
for 2–3 years; then 
every 6–12 months 
for 3 years; and an-
nually thereafter, as 
clinically indicated.
Locally advanced melanoma with metastatic 
nodes, or matted nodes, or in transit met(s)/
satellite(s) (stage IIIA–IIIC)—after primary site 
resection with lymphadenectomy. Resected 
local recurrence or nodal metastases from 
unknown primary site.
H&P with attention to complete skin exam, as well as draining lymph nodes, locore-
gional area, and scar after primary site resection.
USG of the region after the lymphadenectomy.
Chest X-ray.
During the first 3 years, CT and/or ultrasound every 6–12 months and annual brain 
MRI should be considered to screen for recurrent or metastatic disease.
CBC, LFT, and LDH level.
Patients education towards skin self-examination and alarming symptoms of recur-
rence—mandatory.
Every 3 months for 
2 years; then every 
3–6 months for 3 
years; and annually 
thereafter, as clini-
cally indicated.
Metastatic disease (stage IV)—after treatment. Metastatic lesions assessment (CT, USG, and/or PET/CT).
CBC, LFT, and LDH level.
Patients education towards skin self-examination and alarming symptoms of recur-
rence—mandatory.
An individual plan of 
follow-up visits.
PET positron emission tomography, CT computed tomography, LDH lactate dehydrogenase, USG ultrasound sonography
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this may justify performing control MRI in this subset 
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tive and specific in the detection of cerebral metastases 
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chest radiological imaging (e.g., CT or MRI scan) should 
be recommended in asymptomatic patients during the 
first 2–3 years due to higher risk of relapse and for earlier 
qualifying low-tumor burden patients with disease dis-
semination to systemic therapy with new effective drugs 
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Before the era of BRAF/MEK inhibitors, the intensive 
radiological tests following earlier treatment have shown 
limited benefit of survival (about 2 months of increasing 
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definitely proven based on prospective clinical trial.
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